Methadone is a drug that has found widespread utility in the management of opioid addiction and pain. Along with its popularity, methadone has also earned an infamous reputation for causing prolongation of the QT interval and an increased risk of torsades de pointes.
Introduction
The Long QT syndrome (LQTS) is a group of heterogenous disorders characterized by lengthening of the cardiac repolarization caused by alterations in the transmembrane potassium, sodium and calcium currents. This prolongation of the cardiac action potential manifests on the electrocardiogram (ECG) as lengthening of the QT interval. The LQTS can serve as a forerunner to torsade de pointes (TdP) and sudden cardiac death.
LQTS are typically categorized as either congenital or acquired. Modern molecular techniques have enabled the identification of a subclinical or "forme fruste" of the LQTS which is characterized by the presence of an altered genotype which manifests phenotypically in the presence of triggers such as drugs or other predisposing factors.
In the United States alone, at this time there are nearly 1 million users of methadone, including patients who are being treated for opiate addiction and pain. 1 However the association of methadone with prolongation of the corrected QT interval (QTc) and the risk of a potentially fatal arrhythmia, TdP has given rise to intense scrutiny and much deliberation in the community. 2, 3 Methadone induced prolongation of QTc is viewed as an acquired trait. However the possibility of a methadone induced "forme fruste" of LQTS remains unexplored.
Case presentation
A 50-year-old woman with a history of Hepatitis C, acquired immunodeficiency syndrome and a history of intravenous drug use, on methadone maintenance treatment (MMT) presented with a history of recurrent episodes syncope and seizure-like activity. Results of laboratory testing on admission, including serum levels of potassium (4.1 mEq/L) and magnesium (2.2 mEq/L) were unremarkable. The ECG on admission was noted to have QTc of 657 ms (Fig. 1) . A review of the patient's medication list revealed that she was on methadone 210 mg/day (recently tapered down from 360 mg/day), and highly active anti-retroviral therapy (HAART) with Ritonavir and Atazanavir. Telemetry recordings revealed that the "seizures" were associated with episodes of sustained TdP (Fig. 2 ) which were terminated with infusions of magnesium sulfate. A continuous lidocaine infusion was started and no recurrent episodes occurred thereafter. HAART was continued with Raltegravir. Morphine was temporarily substituted in place of methadone; the discontinuation of methadone was accompanied by normalization of the QTc within 24 h.
In light of the fact that our patient had recurrent episodes of TdP while on methadone, a decision was taken to place a dual chamber implantable cardioverter and defibrillator (ICD) prior to the Pointes" or "twisting of the points" to describe the appearance of a ventricular tachycardia where the QRS complexes appeared to oscillate around to the isoelectric line in a sinusoidal pattern.
Congenital LQTS were first recognized in the 1950s and 1960s: The Jervell and Lange-Nielsen syndrome 7 (cardiac phenotype associated with sensorineural deafness) and the Romano-Ward variant 7 (purely cardiac). Congenital LQTS as a channelopathy, was first discovered in 1995 with the identification of mutant voltagegated potassium and sodium channels. 8 To date, nearly a thousand different mutations in thirteen distinct genes designated as LQT1 through to LQT13 have been described. The mutations in LQT1, LQT2 and LQT3 cumulatively account for 75% of all cases of familial LQTS. 8 The other 10 minor LQTS genes make up an additional 5%;
20% of the familial LQTS cases have yet undiscovered genetic loci. 8 The acquired forms of LQTS appear to be the result of interplay between complex cardiovascular traits, exposure to drugs and multiple environmental factors (Table 1) . 2e4,8 Arguably, the most important of these is the association of LQTS with the use of numerous drugs. In fact, QT prolongation and TdP are the most common reasons for the withdrawal of drugs from markets in the U.S. 9, 10 Between the purely congenital and the drug induced forms of LQTS, lies the "forme fruste" of the congenital LQTS. This concept which was first postulated by Moss and Schwartz 11 entails that there is a subset of the population that has a genetic substrate that renders them susceptible to life threatening arrhythmias such as TdP; yet the phenotype remains clinically silent until exposure to triggers (e.g. drugs, hypokalemia etc.) which are thought to diminish the "repolarization reserve", 4,9 leading to prolongation of the QTc and TdP. In 1997, Priori et al and Schulze et al became the first ones to separately identify two such cases of subclinical LQTS. 12 Napolitano et al 12 and Makita et al 13 subsequently identified subclinical mutations in KvLQT1 and SCN5A genes respectively. In both cases, 12, 13 it was hypothesized that the mutations lead to a reduction in repolarizing currents, which remained clinically silent until exposure to cisapride. Administration of cisapride blocked the rapid delayed rectifier potassium current (Ikr) and exhausted the "repolarization reserve" 4,9 which would have otherwise compensated for the loss of function of the mutant channels, leading to prolongation of the QT interval and recurrent episodes of TdP.
Pathophysiology of LQTS
The pathophysiologic mechanisms of the congenital LQTS are outlined in Table 2 .
The vast majority of drug-induced forms of LQTS are mediated through their effects on the Ikr. 9, 10 The human ether-a-go-go gene (HERG or KCNH2) 14 gene encodes a potassium channel protein that regulates the Ikr. 4 The culprit drugs preferentially block the rapid component of the Ikr, 10 resulting in a delay in the Phase 3 of the ventricular or cardiac action potential. The increased duration of the action potential is manifests as QT prolongation. The prolonged repolarization can trigger early afterdepolarizations (EADs) due to activation of inward depolarizing currents, most likely L-type calcium channels or sodiumecalcium exchange current. 10 The EADs can generate ectopic beats or ventricular extrasystoles if they occur in a large enough region of the heart; this "triggered activity" from EADs can serve to initiate TdP. 9, 10 Episodes of drug-induced TdP are typically preceded by a shorte longeshort sequence which is characterized by a premature ventricular complex (PVC), followed by a compensatory pause and then another PVC which sets off TdP. 8, 9 This particular sequence is also thought to increase the transmural heterogeneity of repolarization across the myocardium. 8 Transmural dispersion (or heterogeneity)
of repolarization is a physiologic phenomenon due to variations in ion channels between the different myocardial cells 9 ; if exaggerated has been associated with an increased risk for TdP. The putative mechanism behind drug-induced TdP includes not just exposure to the drug, but also the presence of concomitant factors such as older age, hypokalemia, bradycardia, female sex etc. 2e4,8 Clinical data 15 and in vivo evidence from Langendroff rabbit models 15e17 have established that females have a naturally longer, QTc and have a greater sensitivity to QT interval prolonging drugs. The perception that females are at a greater risk of drug-induced TdP does not stem from any single factor that is inherent to the female gender. Rather, the best evidence at this time suggests that sex hormones in males appear to attenuate drug induced QTc lengthening by regulating the QT interval. 15, 16 Alterations in the expression of cardiac ion channels, regional variations in specific current densities in the myocardium have been postulated as mechanisms through which sex hormones influence cardiac repolarization, although the exact molecular mechanisms remain to be defined. 15, 16 Although it lacks specificity as predictor of the risk of TdP, QT prolongation is used as the surrogate marker for assessing the torsadogenic potential of a drug during development.
18e20 The International guidance for Clinical Evaluation of the QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs (ICH E-14) states that all drugs should be subjected to a "thorough QT/QTc study" prior to registration. Although there is no consensus on the upper limit values of QT interval and changes from baseline, the guidelines suggest a sex-independent threshold for QTc prolongation of 450 ms and QTc above 500 ms as a the critical threshold value.
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The Arizona Center for Education & Research on Therapeutics (Arizona-CERT) 21 maintains an updated database of drugs that are known to prolong the QT interval and pose a risk of TdP. The list can be accessed via the internet (www.torsades.org); it includes methadone, a drug well known for its association with QT prolongation and TdP.
Methadone
Methadone is a long-acting synthetic opioid agonist that has a notorious reputation for causing QTc prolongation and has been associated with a high risk of TdP. 8, 22, 23 It was first proposed as a substitute for heroin in 1965 by Dole and Nyswander. 24 Ever since, it has emerged as a key player both in the management of opioid addiction and as an inexpensive therapy for pain. However, unexpected deaths associated with the use of methadone 24 eventually lead to a clinician safety alert from the U.S. Food and Drug Administration (FDA) in 2006, and a manufacturer's black box warning.
3,25
Mechanism of action
Like most drugs that cause LQTS, methadone too is an inhibitor of the cardiac ion channel KCNH2 26 and causes QT prolongation in a dose dependent manner. 4, 26 Increased QT dispersion (QT interval variability in electrocardiographic leads) is a marker of heterogenous cardiac repolarization and has been observed in association with methadone. 27 In addition to its effects on cardiac repolarization, methadone use is also associated with the development of bradycardia mediated via its anticholinesterase properties 28 and through its action as a calcium channel antagonist. 29 Thus through its multiple effects of QT prolongation, increased QT dispersion and negative chronotropy, methadone poses a significant risk for the development of TdP.
Evidence
The literature on methadone-induced QT prolongation dates back to 1973 when Stimmel et al 30 reported prolongation of the QTc and electrocardiographic abnormalities in narcotic addicts that included methadone treated patients. A plethora of evidence has emerged since that time describing the nexus between QT prolongation and methadone use. A brief summary of the data from clinical case series, cross-sectional, retrospective and prospective studies is provided in Table 3 . 34 did not find any such correlation but they did note that 83% of the patients on long term MMT had a longer baseline QT interval compared with people not on long-term methadone when matched for sex and age. In the largest cross-sectional study to date, Fanoe et al 20 analyzed a cohort of 450 adult heroin addicts, of which 393 were being treated with oral methadone; the QTc interval was reported to increase by 10 ms for every 50 mg increase in the methadone dose.
Prospective data
Prolongation of the QTc interval has been found in five studies 27,30,36e38 of patients receiving oral methadone for either reported an increase in the QT dispersion.
Retrospective data
In a retrospective analysis of patients receiving oral methadone for cancer pain, Reddy et al 39 did not report QTc prolongation at low dose methadone of 30 mg. Ehret et al 40 analyzed 247 hospitalized patients with a history of intravenous drug use and found marked QTc prolongation (>500 ms) in 16% of the 167 patients on methadone therapy; six cases of TdP were also reported. QTc prolongation was not found among the intravenous drug users who were not on methadone. In addition, the study also showed that discontinuation of the methadone was associated with a shorter QTc interval. Kornick et al 41 noted a dose-dependent prolongation of the QTc with the use of intravenous methadone, but not with the use of intravenous morphine.
Randomized trial data
There is a relative paucity of randomized data. In a 17-week randomized study of 220 patients, who were being treated for opioid dependence with levomethadyl (75e115 mg), buprenorphine (16e32 mg), high-dose (60e100 mg) and low-dose (20 mg) methadone, Wedam et al 42 found a prolongation of the QTc interval in 23% of the patients who received methadone and had a normal QTc interval at baseline. In addition, 10% of the methadone treated group had a QTc interval of more than 500msec at some point over the 16-week study period.
Predisposing factors
Prolongation of the QTc is accepted as risk factor for the development of TdP 2 but as is the case with other QTc prolonging drugs, methadone's ability to trigger TdP is thought to be modulated by the presence of several factors. Methadone prolongs QTc in a dose dependent manner. 37, 43 Drugs that increase the plasma concentrations of methadone (e.g. CYP3A4 system inhibitors such as ritonavir, erythromycin etc.) 10 have been identified as risk factors, although their precise role remains unclear at this time. 8 Other factors that predispose to a methadone induced TdP include hypokalemia, 3, 8 
"Subclinical LQTS" and methadone
In spite of the compelling body of evidence linking the use of methadone to prolongation of the QTc interval and development of TdP, the question as to why methadone is not equipotent in triggering TdP across the entire at-risk population of methadone users remains unanswered. As mentioned earlier in this review, one possibility that remains unexplored is a methadone-induced TdP may represent a "forme fruste" of congenital LQTS.
Genetic susceptibility to drug induced cardiac arrhythmias, whether due to LQTS causing mutations or the presence of functional single nucleotide polymorphisms is now an irrefutable fact. It merits consideration in cases of drug-induced LQTS and TdP, particularly with regard to high risk drugs such as anti-arrhythmic drugs and methadone. 8 The works of Priori et al, 12 Schulze et al 12 and Makita et al 13 raise the possibility that not all the cases of drug-induced arrhythmias occur in a sporadic and unpredictable manner; that in fact there may be individuals who are predisposed to developing potentially life-threatening arrhythmias and may stand to benefit if they can be identified. Clinical studies of congenital LQTS have shown evidence of incomplete penetrance, as low as 25%, 45 which implies that family members of patients afflicted with LQTS who are considered to be "normal" i.e. without phenotypical evidence of prolonged QT may still be silent gene carriers who are at risk of developing TdP if exposed to offenders. Thus the cumulative population that stands to be affected by a given drug extends not only to these "silent carriers", but can also afflict 50% of their offspring as the genes are transmitted in an autosomal dominant fashion. If the concept of a "forme fruste" of familial LQTS is extrapolated to methadone, the hypothesis can portend far reaching clinical consequences. The yield from genetic testing of the three major LQTS susceptibility genes i.e. LQT1, LQT2 and LQT3 is approximately 10%e15% in cases of isolated drug-induced acquired LQTS.
46e48 Polymorphisms affecting cardiac channel genes (e.g.
LQT3-like syndrome resulting from polymorphism affecting SCN5A-S1103Y) which contribute to a reduced repolarization reserve and hence increased susceptibility to arrhythmias 8, 10 have also been identified. 8 Case series of drug-induced TdP have implicated subclinical congenital LQTS in 5%e20% of cases. 46e48 If these results are projected on to the nearly 250,000 patients in opioid treatment programs 1 and the nearly 720,000 patients receiving methadone for chronic pain syndromes throughout the United States, 1 the consequences can be momentous; this excludes the potential at-risk population that may result from the autosomal dominant transmission of this genetic trait. Not only would such a relationship call for a need to identify and screen "at risk" individuals and families, but would also call for greater vigilance in monitoring for development of TdP. Methadone continues to play a pivotal role in the treatment of opioid addiction and pain management. MMT programs have been hugely successful in reducing rates of addiction related crimes, reduction in the transmission of diseases including human immunodeficiency virus. 44 Methadone has also been shown to reduce mortality among intravenous drug users and treated versus untreated heroin addicts. 1, 10 Thus the pharmaco epidemiologic implications of finding a genetic culprit for at least a proportion of methadone drug users who develop TdP are potentially staggering. The problem is compounded by the fact that methadone is a medication with few therapeutic alternatives. Buprenorphine is an FDA approved medication for patients on methadone who develop marked QTc prolongation or TdP 1 ; it has not been associated with TdP. 27, 42 However, data from randomized control trails indicates that buprenorphine has lower retention rates than methadone, thus necessitating the continuation of methadone in dependent patients. 44 
Management
The management of methadone-induced prolongation of the QTc and TdP revolves around diligent monitoring to reduce the risk of TdP and the management of TdP, should it occur.
In view of the significant risk of TdP to methadone users, an expert panel was convened, which issued a set of guidelines 1 that is applicable to all patients either currently under treatment with methadone or being considered for the initiation of methadone treatment for addiction or pain, the only exception being patients with terminal, intractable cancer pain. To reduce the risk of TdP, the guidelines state the following: 1) notifying patients of arrhythmia risk when prescribing methadone, 2) inquiring about history of arrhythmia, syncope, and structural heart disease, 3) obtaining a pre-treatment ECG to measure the QTc interval and follow- Our patient, for all practical purposes, presented a case of acquired QT prolongation secondary to methadone use. Given the clinical implications and risks associated with placement of an ICD, the prudent next step would have been to place the patient on a trial of buprenorphine, as a substitute for methadone. However, the management of our patient posed a dilemma for several reasons: our patient had a long standing history of being on MMT (>7 years), and was not agreeable to using buprenorphine instead of methadone. Given the likelihood of non-compliance in this case, coupled with the fact that buprenorphine has low retention rates in methadone dependent patients, the decision to place an ICD, albeit perhaps a bit hastily, was undertaken.
Our patient had multiple risk factors for methadone-induced TdP: female sex; exposure to QT prolonging drugs, Atazanavir and Ritonavir. 21 Ritonavir is also a CY3A4 inhibitor. 40 Genetic testing in this case of methadone-induced QTc prolongation and TdP, unfortunately could not be undertaken as informed consent could not be obtained from the patient.
Conclusions
The evolution of elegant molecular studies, together with the identification of environmental stressors has now raised the possibility of a new paradigm in drug-induced LQTS; a common model in which the genetic factors alter the manifestation of clinical phenotypes. The possibility that methadone-induced TdP may represent a "forme fruste" of LQTS remains uncharted. Should such an association be discovered, it would have far reaching pharmacoeconomic implications, both in terms of ensuring the availability of drugs for the population that requires them, but making certain the avoidance of their use in genetically predisposed individuals in whom potentially life-threatening effects may occur.
